All

FDA Clears AlphaVac F1885 System for Treatment of Pulmonary Embolism

The clearance broadens the applicability of the AlphaVac F1885 System in the non-surgical removal of thrombi or emboli from the venous vasculature.

All

Short Sleep Tied to Increased Risk of Peripheral Artery Disease

Sleeping less than five hours a night is associated with a 74% raised likelihood of developing peripheral artery disease (PAD) compared with seven to eight hours of sleep.

All

COVID mRNA Vaccines Safe in Heart Failure Patients

COVID mRNA vaccines are associated with a decreased risk of death in patients with heart failure, and the vaccines were not associated with an increased risk of worsening heart failure, venous thromboembolism or myocarditis in heart failure patients.

FDA De Novo Clearance for Philips CavaClear IVC Filter Removal Laser Sheath

by RT Staff | Dec 22, 2021 | Cardiopulmonary & Thoracic, Pulmonary Embolism | 0

The FDA has granted De Novo Clearance for the Philips CavaClear, an IVC Filter Removal Laser Sheath used to remove an IVC filter when previous methods of removal have failed, according to the company.

New Guidelines for Antithrombotic Therapy for VTE

by RT Staff | Aug 18, 2021 | Cardiopulmonary & Thoracic, Clinical, Pulmonary Embolism | 0

Chest has released new clinical guidelines for venous thromboembolism (VTE) management, that provides 29 recommendations.

Clinical Trial for Endovascular System Begins

by RT Staff | Aug 12, 2021 | Clinical Trials, Pulmonary Embolism, Therapy Devices | 0

Boston Scientific has begun enrollment in a clinical trial comparing use of the EkoSonic Endovascular System (EKOS) in combination with anticoagulation to anticoagulation alone for the treatment of acute, intermediate-high-risk pulmonary embolism.

FDA Approves Pradaxa to Treat VTE in Children Age 3 Months to 12 Years Old

by RT Staff | Jun 21, 2021 | Cardiopulmonary & Thoracic, FDA Approvals, US Pharmaceuticals | 0

The FDA approved Pradaxa oral pellets to treat children 3 months to less than 12 years old with venous thromboembolism directly after they have been treated with a blood thinner given by injection for at least five days.

COVID-19 Is Linked To Rare Recurrent Blood Clots

by RT Staff | May 15, 2021 | Infectious Diseases | 0

Researchers at Rutgers Robert Wood Johnson Medical School are reporting the first instance of COVID-19 triggering a rare recurrence of potentially serious blood clots in people’s arms.

Management of Acute Pulmonary Embolism

by RT Staff | Apr 25, 2021 | Critical Care, Pulmonary Embolism | 0

Only a small percentage of hospitalized patients with acute pulmonary embolism are discharged home from the emergency department, according to new research in the Academic Emergency Medicine journal.

How Common Is Pulmonary Embolism in Hospitalized COPD Patients?

by RT Staff | Jan 17, 2021 | COPD | 0

COPD patients who were hospitalized for respiratory symptoms had a prevalence of pulmonary embolism of 5.9%.

COVID-19 Patients Treated for Blood Clots Showed Rapid Improvement

by RT Staff | Apr 15, 2020 | Other Infections, Pulmonary Embolism | 0

A small study of five patients with COVID-19 found that treatment with tPA — a thrombolyic agent used to dissolve blood clots — resulted in rapid improvement in alveolar ventilation, oxygenation, and/or shock.

Study: Deep Vein Thrombosis Incidence and Pulmonary Embolism

by RT Staff | Mar 23, 2020 | Disorders & Diseases | 0

New research suggests that there may be a reduced incidence of deep vein thrombosis (DVT) in patients who are at high risk of pulmonary embolism (PE).

First Eliquis Generics Approved for DVT, Pulmonary Embolism

by RT Staff | Jan 8, 2020 | Business News, Cardiopulmonary & Thoracic, FDA Approvals, Pulmonary Embolism, US Pharmaceuticals | 0

The first two generics of Eliquis (apixaban) have been approved for cardiopulmonary conditions, including deep vein thrombosis and pulmonary embolism.